By Dr. Neil Taylor
As AI-driven scientific research accelerates the drug discovery process, much of the attention has focused on the impact of new models, algorithms and compute. Garnering far less attention is a quieter, more fundamental, and no less crucial constraint: how protein structure data is labelled, validated and maintained over time.
For AI to be genuinely effective in drug discovery and computational chemistry, models require access to high-quality, accessible and up-to-date protein structure data enriched with meaningful, consistent metadata. This is the fuel that it runs on, and when poor quality data enters the AI engine, the process can stutter to a halt. Then, as the science evolves, the data must evolve too. Managing this complexity cannot be peripheral to the process. It requires robust scientific data infrastructure designed both for today’s technology and for future-focused research possibilities. This comes with data management challenges unique to the industry.
“The data challenge is not simply one of scale. It is structural.”
Every protein structure represents a convergence of information from multiple dimensions: experimental method, biological context, validation metrics and, increasingly, predictive models. Each of these dimensions introduces its own data labelling requirements, and those requirements are constantly changing as new techniques emerge and scientific understanding deepens.
Unlike many AI domains, protein structure data cannot be reduced to static labels applied once and forgotten. What was sufficient metadata five years ago is likely inadequate today, and could be actively misleading for modern AI models.
This is particularly acute in AI-driven drug discovery, where the same structure may be used simultaneously for structure prediction, binding affinity modelling, selectivity analysis and toxicity assessment. Each use case demands different labels, different validation criteria and different interpretations of quality.
Structure determination data varies by method. X-ray crystallography, cryo-EM and AI-based predictions each require distinct metadata: resolution, confidence metrics, validation scores, authorship and date of determination. These attributes are not interchangeable, and AI models are sensitive to those differences.
Validation layers add further complexity. Sequence validation, ligand identification, electron density quality and model confidence all require rigorous documentation. Crucially, today’s validation data becomes tomorrow’s AI training data – meaning inconsistencies or omissions propagate forward.
Biological context is rarely universal. An antibody scientist needs CDR annotations. A kinase expert cares about DFG states. Target family classifications, UniProt identifiers and off-target relationships must all be captured, cross-referenced and kept current. The same structure can legitimately mean very different things to different researchers.
Modality diversity compounds the issue. Modern drug discovery spans small molecules, nucleotides, peptides, monoclonal antibodies, bispecifics, multispecific formats, non-canonical antibody scaffolds, ADCs and PROTACs. Each modality introduces its own labelling schemas and validation needs.
Functional validation data extends beyond structure entirely. Affinity measurements from biochemical assays, cellular systems and animal models carry their own metadata: assay type, experimental conditions, timing and provenance. Without this temporal and contextual information, AI models struggle to assess relevance and reliability.
Finally, AI training requirements impose their own constraints. Data must be partitioned into training, validation and test sets for tasks such as structure prediction, affinity modelling and toxicity estimation. The integrity of these datasets directly determines model performance and trustworthiness.
The solution is not “another database”. What AI-enabled research demands is fit-for-purpose infrastructure. In this case, a research-oriented enterprise data resource that can adapt as science changes, without requiring wholesale redesign every few years.
At a minimum, such a system must:
This is where Desert Scientific software sits conceptually. Our tools are not the AI layers themselves, but as the scientific data infrastructure that makes reliable AI possible in the first place, particularly in structure-based drug design and structural biology workflows. This infrastructure opens up the potential for organisations to use their own AI-driven workflows, seamlessly integrating private and public data sources in a consistently accessible, high quality database that opens up collaboration opportunities across the organisation.
This challenge is not theoretical. Platforms such as DesertSci’s Proasis demonstrate that SQL-based, research-oriented protein structure databases can support dynamic metadata, complex validation layers and evolving labelling requirements at scale. By integrating structural data, sequence information and contextual annotations within a single system, such tools reflect how real drug discovery teams work, and how AI models must ultimately be trained.
The open question is not whether this approach works; it is how broadly the scientific research community can adopt infrastructure that treats data labelling as a high-priority, evolving concern rather than an afterthought.
AI may be the visible engine of modern drug discovery, but data labelling for protein structures is part of the foundation it rests on.
As AI transforms scientific research, data infrastructure must transform with it. The performance of AI models will only ever be as good as the quality, consistency and adaptability of the data used to train them. That means building infrastructure now that’s designed to grow and change with science, rather than systems that require reinvention every few years.
Organisations that succeed in this new era will be those that recognise the value in investing early in robust, flexible scientific data systems – not just to generate data, but to organise, validate and label it in ways that serve both current research needs and future AI applications.
Or, if you’d like to arrange a demonstration of DesertSci’s Proasis, please get in touch with our team.
